bTMB is a promising predictive biomarker
Sign Up to like & getrecommendations! Published in 2019 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/s41571-019-0202-8
Abstract: Nature reviews | CliniCal OnCOlOgy tumour mutational burden (tMB) is a promising biomarker of a response to immunecheckpoint inhibitors, independent of programmed cell death 1 ligand 1 (PDL1) status. tMB is usually measured in DNa… read more here.
Keywords: biomarker; tissue; cancer; tmb ... See more keywords
Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-004064
Abstract: Background Patients treated with immunotherapy are at risk of considerable adverse events, and the ongoing struggle is to accurately identify the subset of patients who will benefit. Tumor mutational burden (TMB) has emerged as a… read more here.
Keywords: tumor; blood; btmb; tumor mutational ... See more keywords
Abstract CT194: Exploratory subgroup analysis of atezolizumab (atezo) clinical characteristics in patients (pts) with low circulating tumor DNA (ctDNA) in B-F1RST—a Phase II trial evaluating blood-based tumor mutational burden (bTMB) in NSCLC
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2019-ct194
Abstract: Background B-F1RST (ITT, n = 152) was the first prospective trial to evaluate bTMB as a predictive biomarker in 1L NSCLC. In the biomarker evaluable population (BEP, ctDNA with max somatic allele frequency [MSAF] ≥… read more here.
Keywords: subgroup analysis; ctdna; trial; btmb ... See more keywords
Abstract 3376: Non-small cell lung cancer (NSCLC) with higher blood tumor mutational burden (bTMB)/tissueTMB (tTMB) ratio is associated with inferior survival outcome
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3376
Abstract: Background: High TMB is known to correlate with better response to immune checkpoint inhibitor (ICI) treatment in certain cancers. bTMB is now being used in place of tTMB at times due to difficulty in obtaining… read more here.
Keywords: ttmb; btmb ttmb; ttmb ratio; btmb ... See more keywords
Abstract CT216: Response to first-line (1L) pembrolizumab (pembro) + chemotherapy (chemo) in non-small cell lung cancer (NSCLC) by blood tumor mutational burden (bTMB): the phase 2 KEYNOTE-782 trial
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct216
Abstract: Background: 1L pembro + platinum-based chemo has shown clinical activity in metastatic NSCLC regardless of tissue tumor mutational burden (tTMB) status. bTMB assessed using circulating tumor DNA in plasma may be a surrogate for tTMB.… read more here.
Keywords: cell; tumor mutational; btmb; pembro ... See more keywords
Maximum Somatic Allele Frequency in Combination With Blood-Based Tumor Mutational Burden to Predict the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer: A Pooled Analysis of the Randomized POPLAR and OAK Studies
Sign Up to like & getrecommendations! Published in 2019 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2019.01432
Abstract: Background: Blood-based tumor mutational burden (bTMB) was recently found to be suboptimal in predicting overall survival (OS) benefits of atezolizumab over docetaxel among patients with advanced non-small cell lung cancer (NSCLC). The maximum somatic allele… read more here.
Keywords: combination; tumor; blood based; btmb ... See more keywords
Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14225649
Abstract: Simple Summary Recent studies exhibited the unstable prediction ability of blood-based tumor mutational burden (bTMB) when predicting the response of immune checkpoint inhibitors (ICIs) therapy in patients with non-small cell lung cancer (NSCLC). Circulating tumor… read more here.
Keywords: tumor mutational; btmb; blood based; based tumor ... See more keywords
Prognostic and Predictive Value of Blood Tumor Mutational Burden in Patients With Lung Cancer Treated With Docetaxel.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the National Comprehensive Cancer Network : JNCCN"
DOI: 10.6004/jnccn.2019.7383
Abstract: BACKGROUND Biomarkers for chemotherapy efficacy in non-small cell lung cancer (NSCLC) are lacking. This retrospective study assesses the association between blood-based tumor mutational burden (bTMB) and clinical benefit of chemotherapy. METHODS Clinical and targeted next-generation… read more here.
Keywords: tumor mutational; value; lung cancer; btmb ... See more keywords